Profile data is unavailable for this security.
About the company
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
- Revenue in USD (TTM)0.00
- Net income in USD-26.25m
- Incorporated2017
- Employees58.00
- LocationBiomx Inc708 Quince Orchard Rd, Suite 205GAITHERSBURG 20878United StatesUSA
- Phone+972 72394-2377
- Fax+1 (800) 253-5177
- Websitehttps://www.biomx.com/
More ▼
Mergers & acquisitions
| Acquired company | PHGE:ASQ since announced | Transaction value |
|---|---|---|
| Adaptive Phage Therapeutics Inc | 235.52% | 2.11m |
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics Inc | 0.00 | -15.75m | 12.13m | 7.00 | -- | 1.65 | -- | -- | -1.86 | -1.86 | 0.00 | 0.7209 | 0.00 | -- | -- | 0.00 | -108.73 | -66.55 | -126.30 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.70m | 12.35m | 82.00 | -- | 0.2067 | -- | -- | -3.49 | -3.49 | 0.00 | 2.58 | 0.00 | -- | -- | 0.00 | -98.52 | -- | -127.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 70.00k | -1.24m | 12.52m | 22.00 | -- | 1.03 | -- | 178.88 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
| Apollomics Inc | 0.00 | -57.11m | 12.90m | 45.00 | -- | 0.6184 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 13.19m | 4.00 | -- | -- | -- | 17,582.44 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.25m | 13.81m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 13.81m | 64.00 | -- | -- | -- | 1.55 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.83m | 2.00 | 3.56 | 0.2913 | 3.08 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 3.30m | -11.46m | 13.94m | 49.00 | -- | -- | -- | 4.23 | -16.80 | -16.80 | 0.8311 | -- | -- | -- | -- | 67,244.90 | -- | -100.11 | -- | -131.65 | -- | -- | -347.86 | -131,560.30 | -- | -- | -- | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.67m | 13.98m | 28.00 | -- | 0.2677 | -- | -- | -1.18 | -1.18 | 0.00 | 2.08 | 0.00 | -- | -- | 0.00 | -39.73 | -47.03 | -42.67 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0232 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Hcw Biologics Inc | 3.92m | -38.37m | 14.00m | 45.00 | -- | -- | -- | 3.57 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -24.83m | 14.14m | 2.00 | -- | -- | -- | -- | -1.62 | -1.62 | 0.00 | -1.70 | 0.00 | -- | -- | -- | -197.97 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -189.12 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| OpGen Inc | 1.96m | -22.39m | 14.20m | 100.00 | -- | -- | -- | 7.23 | -20.01 | -20.01 | 1.66 | -8.65 | 0.1553 | -- | 6.09 | -- | -176.99 | -87.95 | -15,455.17 | -127.65 | 3.15 | 15.42 | -1,139.66 | -794.78 | -- | -20.25 | -- | -- | 31.11 | 3.02 | 12.38 | -- | 40.20 | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.02m | 14.99m | 3.00 | -- | 3.62 | -- | -- | -0.0175 | -0.0175 | 0.00 | 0.024 | 0.00 | -- | -- | 0.00 | -34.83 | 27.48 | -34.99 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 15.45m | 26.00 | -- | 2.28 | -- | 76.87 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
Data as of Nov 09 2024. Currency figures normalised to Biomx Inc's reporting currency: US Dollar USD
0.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Barclays Bank (Suisse) SAas of 30 Jun 2024 | 25.00k | 0.14% |
| UBS Securities LLCas of 30 Jun 2024 | 4.88k | 0.03% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 2.28k | 0.01% |
| XTX Markets LLCas of 30 Jun 2024 | 2.08k | 0.01% |
| PNC Bank, NA (Investment Management)as of 30 Sep 2024 | 400.00 | 0.00% |
| Millennium Management LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Jump Trading LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Raymond James Financial Services Advisors, Inc.as of 30 Sep 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
